<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30184027</article-id><article-id pub-id-type="pmc">6122754</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2017-0247</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Predictive Value of Mean Platelet Volume in Saphenous Vein Graft
Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kaya</surname><given-names>Ugur</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Koza</surname><given-names>Yavuzer</given-names></name><xref ref-type="aff" rid="aff2">2</xref><role>MD</role></contrib></contrib-group><aff id="aff1">
<label>1</label> Department of Cardiovascular Surgery, Ataturk University, Faculty
of Medicine, Erzurum, Turkey.</aff><aff id="aff2">
<label>2</label> Department of Cardiology, Ataturk University, Faculty of Medicine,
Erzurum, Turkey.</aff><author-notes><corresp id="c1">Correspondence Address: Ugur Kaya, Department of Cardiovascular
Surgery, Faculty of Medicine, Ataturk University, 25240 Erzurum, Turkey. E-mail:
<email>dr.ugurum@hotmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Jul-Aug</season><year>2018</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Jul-Aug</season><year>2018</year></pub-date><volume>33</volume><issue>4</issue><fpage>317</fpage><lpage>322</lpage><history><date date-type="received"><day>22</day><month>12</month><year>2017</year></date><date date-type="accepted"><day>17</day><month>2</month><year>2018</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>To determine whether mean platelet volume (MPV), platelet distribution width
(PDW), and platelet count could be used as determinants of mortality
following coronary artery bypass graft (CABG) surgery and patency of
saphenous vein grafts (SVG).</p></sec><sec><title>Methods</title><p>The records of 128 patients who underwent emergency or elective coronary
angiography after CABG surgery, and who died at an early stage were
retrospectively reviewed. Patients were divided into three groups as early
death, no SVG disease (SVGD), and SVGD group. MPV, PDW, and platelet count
were evaluated at different times.</p></sec><sec><title>Results</title><p>MPV was significantly higher in the stenotic group than in the nonstenotic
group (9.7&#x000b1;1.8 fl and 8.2&#x000b1;0.9 fl, <italic>P</italic>&#x0003c;0.05).
The postoperative MPV ratio was found to be higher in the stenotic group
when compared to the preoperative period (9.6&#x000b1;1.8 fl and
7.8&#x000b1;0.9 fl, <italic>P</italic>&#x0003c;0.05). MPV values were also found
to be higher in patients who died during the early stage than in surviving
patients (9.4&#x000b1;1.9 fl and 8.0&#x000b1;1.0 fl,
<italic>P</italic>&#x0003c;0.05). There was no statistically significant
difference regarding platelet count and PDW ratios between the early deaths
group and surviving patients. An MPV value higher than 10.6 predicted SVGD
with 85% sensitivity and 45% specificity; and an MPV higher than 7.9
predicted early death with 80% sensitivity and 68% specificity were
observed.</p></sec><sec><title>Conclusion</title><p>MPV may be a useful indicator for the prediction of SVGD and mortality
following CABG surgery.</p></sec></abstract><kwd-group><kwd>Saphenous Vein/Pathology/*Transplantation</kwd><kwd>Hyperplasia</kwd><kwd>Thrombosis</kwd><kwd>Arteriosclerosis</kwd><kwd>Mean Platelet Volume</kwd><kwd>Coronary Artery Bypass</kwd></kwd-group></article-meta></front><body><table-wrap id="t5" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="10%" span="1"/><col width="90%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ASA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Acetylsalicylic
acid</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CABG</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Coronary artery bypass
graft</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">EDTA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">=
Ethylenediaminetetraacetic acid</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">EF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Ejection fraction</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LIMA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left internal mammary
artery</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">MPV</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Mean platelet
volume</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">PDW</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Platelet distribution
width</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ROC</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Receiver operating
characteristic</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Standard deviation</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SVG</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Saphenous vein
grafts</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SVGD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Saphenous vein grafts
disease</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Coronary artery bypass graft (CABG) surgery is a commonly used treatment method for
stenotic coronary artery revascularization. Saphenous veins and arterial grafts are
widely used in CABG surgery. The patency rates of saphenous vein grafts (SVG) are
relatively low. A 10-year patency rate for SVG was reported as 61%<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>.</p><p>Different processes have been proposed for SVG disease (SVGD), including thrombosis,
intimal hyperplasia, and atherosclerosis. The contribution of these processes may
differ among patients. Therefore, many studies have been conducted to identify risk
indicators during SVGD. Platelets are known to play an important role in the
pathophysiology of coronary artery disease and SVGD. The main effect of platelets
known to have activity in atherogenesis, which begins with the endothelial injury,
is atherothrombosis, a dangerous complication in the advanced stage of
atherosclerosis<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>. Mean platelet volume (MPV) is an important indicator of
platelet activation. Platelet distribution width (PDW) and platelet count have also
been associated with SVGD<sup>[<xref rid="r2" ref-type="bibr">2</xref>-<xref rid="r4" ref-type="bibr">4</xref>]</sup>.</p><p>We aimed to determine whether MPV and PDW values and platelet count could be used as
predictive parameters for early death after CABG surgery and graft occlusion during
SVGD.</p></sec><sec sec-type="methods"><title>METHODS</title><p>This retrospective study included 128 patients (77 males, 51 females) who underwent
emergency or elective coronary angiography after CABG surgery, between 2010 and
2017, and who died during the early stages (de&#x0fb01;ned as in-hospital or 60-day
mortality). All operations were performed by a single surgical team. Patients were
divided into three groups according to SVG patency and early death: Group I, early
death (n=30, 19 males, 11 females, mean age 62.3&#x000b1;9.6); Group II, nonstenotic
group (n=49, 28 males, 21 females, mean age 59.9&#x000b1;10.6); and Group III,
stenotic group (SVGD) (n=49, 30 males, 19 females, mean age 61.7&#x000b1;11.7).
Coronary angiographies of patients were assessed by two independent examiners.
Stenosis of 50% or more in SVG was considered hemodynamically significant. Patients
underwent CABG operation included at least the use of one SVG. The left internal
mammary artery (LIMA) was used in all patients, except eight.</p><p>Indications for coronary angiography were as follows: recurrent postoperative stable
angina pectoris, unstable angina pectoris, myocardial infarction, and preoperative
evaluation for non-cardiac surgeries. Before the angiography procedure, medical
history and risk factors for coronary heart disease of all patients were evaluated.
Patients with SVG and problems in the native artery anastomosis path, those with
severe cardiac valve disease and other diseases with cardiac manifestations
(<italic>e.g.,</italic> ventricular septal rupture and dissection), patients
with renal and hepatic dysfunction, patients with acute and chronic infections, and
patients with bone marrow problems were excluded from the study. Pre and
postoperative MPV and PDW values and platelet counts were obtained from hospital
records and compared among all groups. Patients included in the study were also
evaluated with regards to risk factors, such as age, gender, cigarette smoking,
diabetes mellitus, hypertension, hyperlipidemia, drug use, ejection fraction (EF),
creatinine clearance, and survival after surgery.</p><p>An approval of the local Ethics Committee was obtained for this study. A written
informed consent was obtained from each patient. The study was conducted in
accordance with the principles of the Declaration of Helsinki. Demographic
information, postoperative data, and operative details were retrospectively
collected from medical records and the Hospital Electronic Record System.</p><p>Laboratory Analysis: MPV-d, PDW-d, and platelet count-d values were measured at the
time of diagnosis (d). MPV-ca, PDW-ca, and platelet count-ca values were assessed at
the time of control angiography (ca).</p><p>The blood samples were obtained using ethylenediaminetetraacetic acid (EDTA) for
anticoagulation. MPV and PDW values were analyzed with aperture-impedance
technology, using the Beckman Coulter Gen-S (Beckman Coulter Corporation, Miami,
USA; GEN-S) device. Impedance reference values were determined as 6.8-10.8 fl for
MPV and 10.0-14.0 fl for PDW.</p><sec><title>Statistical Analysis</title><p>Statistical analysis was performed using SPSS package (version 20.0; SPSS for
Windows, Chicago, IL, USA). Descriptive statistics were reported, including
mean, standard deviation (SD), median, interquartile range, and percentage. The
t-test was used in comparisons of the deceased and surviving patients; it was
also used in comparisons of patient groups with and without SVGD. Receiver
operating characteristic (ROC) curves were analyzed to assess the optimal
cut-off values of influence factors. Sensitivity and specificity were calculated
for the chosen cut-off values. <italic>P</italic>&#x0003c;0.05 was considered
statistically significant.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>A total of 128 patients were evaluated in this study; 77 (60.2%) males and 51 (39.8%)
females. Demographic characteristics of these patients and laboratory results are
shown in <xref rid="t1" ref-type="table">Table 1</xref>. Low EF value and cigarette
smoking in the stenotic (SVGD) group were found to be statistically significant
(0.043 and 0.016, respectively; <italic>P</italic>&#x0003c;0.05).</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline clinical characteristics of patients with or without saphenous vein
graft disease.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Nonstenotic group<break/>(n=49)</th><th align="center" rowspan="1" colspan="1">Stenotic group<break/>(n=49)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (mean &#x000b1; SD)</td><td align="center" rowspan="1" colspan="1">59.9&#x000b1;10.6</td><td align="center" rowspan="1" colspan="1">61.7&#x000b1;11.7</td><td align="center" rowspan="1" colspan="1">0.39</td></tr><tr><td align="left" rowspan="2" colspan="1">Sex (male/female)</td><td align="center" rowspan="1" colspan="1">Males 28 (57.1%)</td><td align="center" rowspan="1" colspan="1">Males 30 (61.2%)</td><td align="center" rowspan="1" colspan="1">0.18</td></tr><tr><td align="center" rowspan="1" colspan="1">Females 21 (42.9%)</td><td align="center" rowspan="1" colspan="1">Females 19 (38.8%)</td><td align="center" rowspan="1" colspan="1">0.15</td></tr><tr><td align="left" rowspan="1" colspan="1">Time of angiography after surgery</td><td align="center" rowspan="1" colspan="1">2.9&#x000b1;2.5 (years)</td><td align="center" rowspan="1" colspan="1">3.5&#x000b1;2.5 (years)</td><td align="center" rowspan="1" colspan="1">0.16</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension</td><td align="center" rowspan="1" colspan="1">20 (40.8%)</td><td align="center" rowspan="1" colspan="1">22 (44.8%)</td><td align="center" rowspan="1" colspan="1">0.13</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus</td><td align="center" rowspan="1" colspan="1">28 (57.1%)</td><td align="center" rowspan="1" colspan="1">31 (63.3%)</td><td align="center" rowspan="1" colspan="1">0.79</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking</td><td align="center" rowspan="1" colspan="1">8 (16.1%)</td><td align="center" rowspan="1" colspan="1">17 (34.7%)</td><td align="center" rowspan="1" colspan="1">0.016</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypercholesterolemia</td><td align="center" rowspan="1" colspan="1">18 (36.7%)</td><td align="center" rowspan="1" colspan="1">21 (42.9%)</td><td align="center" rowspan="1" colspan="1">0.81</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine (mg/dL)</td><td align="center" rowspan="1" colspan="1">1.09&#x000b1;0.9</td><td align="center" rowspan="1" colspan="1">1.17&#x000b1;0.4</td><td align="center" rowspan="1" colspan="1">0.92</td></tr><tr><td align="left" rowspan="1" colspan="1">Ejection fraction (%)</td><td align="center" rowspan="1" colspan="1">58.3&#x000b1;5.3</td><td align="center" rowspan="1" colspan="1">50.21&#x000b1;9.2</td><td align="center" rowspan="1" colspan="1">0.043</td></tr><tr><td align="left" rowspan="1" colspan="1">Aspirin</td><td align="center" rowspan="1" colspan="1">43 (87.8%)</td><td align="center" rowspan="1" colspan="1">45 (91.8%)</td><td align="center" rowspan="1" colspan="1">0.95</td></tr><tr><td align="left" rowspan="1" colspan="1">Statins</td><td align="center" rowspan="1" colspan="1">26 (53.1%)</td><td align="center" rowspan="1" colspan="1">30 (61.2%)</td><td align="center" rowspan="1" colspan="1">0.89</td></tr><tr><td align="left" rowspan="1" colspan="1">Internal mammary artery graft</td><td align="center" rowspan="1" colspan="1">45 (91.8%)</td><td align="center" rowspan="1" colspan="1">46 (93.9%)</td><td align="center" rowspan="1" colspan="1">0.18</td></tr><tr><td align="left" rowspan="1" colspan="1">Saphenous vein grafts per patients</td><td align="center" rowspan="1" colspan="1">2.3&#x000b1;0.9</td><td align="center" rowspan="1" colspan="1">2.6&#x000b1;0.9</td><td align="center" rowspan="1" colspan="1">0.21</td></tr><tr><td align="left" rowspan="1" colspan="1">EuroSCORE</td><td align="center" rowspan="1" colspan="1">4.16&#x000b1;2.79</td><td align="center" rowspan="1" colspan="1">4.30&#x000b1;2.89</td><td align="center" rowspan="1" colspan="1">0.36</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>SD=standard deviation</p></fn></table-wrap-foot></table-wrap><p>Comparisons were made between patients with stenosis (SVGD) and no stenosis regarding
MPV-d and MPV-ca; PDW-d and PDW-ca; and platelet count-d and platelet count-ca
values. MPV-ca value was found to be statistically significantly higher in the
stenotic group (Group III) than in the nonstenotic group (Group II) (9.7&#x000b1;1.82
and 8.2&#x000b1;0.94, respectively; <italic>P</italic>&#x0003c;0.05). PDW-ca value was
16.3&#x000b1;0.9 in the nonstenotic group (Group II) and 16.5&#x000b1;1.5 in the
stenotic group (Group III); results were found to be statistically insignificant
(<italic>P</italic>=0.43) (<xref rid="t2" ref-type="table">Table 2</xref>).
Comparison of the preoperative (at the time of diagnosis) and postoperative (at the
time of control angiography) values in the stenotic group (Group III) demonstrated
that the high MPV value during control angiography was statistically significant
about the preoperative period (9.6&#x000b1;1.8 and 7.8&#x000b1;0.9, respectively;
<italic>P</italic>&#x0003c;0.05) (<xref rid="t3" ref-type="table">Table 3</xref>).
ROC curve for MPV, PDW, and platelet count in patients with stenosis (SVGD, Group
III) is shown in <xref ref-type="fig" rid="f1">Figure 1</xref> and the comparison of
MPV values in the nonstenotic patients (Group II) is shown in <xref ref-type="fig" rid="f2">Figure 2</xref>. An MPV value higher than 10.6 fl had 85% sensitivity
and 45% specificity.</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Comparison of patients with or without saphenous vein graft disease.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Nonstenotic group<break/>(n=49)</th><th align="center" rowspan="1" colspan="1">Stenotic group<break/>(n=49)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">MPV-d</td><td align="center" rowspan="1" colspan="1">8.1&#x000b1;1.13</td><td align="center" rowspan="1" colspan="1">7.9&#x000b1;0.99</td><td align="center" rowspan="1" colspan="1">0.37</td></tr><tr><td align="left" rowspan="1" colspan="1">MPV-ca</td><td align="center" rowspan="1" colspan="1">8.2&#x000b1;0.94</td><td align="center" rowspan="1" colspan="1">9.7&#x000b1;1.82</td><td align="center" rowspan="1" colspan="1">0.0003</td></tr><tr><td align="left" rowspan="1" colspan="1">PDW-d</td><td align="center" rowspan="1" colspan="1">16.7&#x000b1;0.94</td><td align="center" rowspan="1" colspan="1">16.7&#x000b1;1.11</td><td align="center" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">PDW-ca</td><td align="center" rowspan="1" colspan="1">16.3&#x000b1;1.83</td><td align="center" rowspan="1" colspan="1">16.5&#x000b1;1.52</td><td align="center" rowspan="1" colspan="1">0.42</td></tr><tr><td align="left" rowspan="1" colspan="1">Platelet count-d</td><td align="center" rowspan="1" colspan="1">249,000&#x000b1;101,500</td><td align="center" rowspan="1" colspan="1">272,000&#x000b1;93,000</td><td align="center" rowspan="1" colspan="1">0.26</td></tr><tr><td align="left" rowspan="1" colspan="1">Platelet count-ca</td><td align="center" rowspan="1" colspan="1">224,000&#x000b1;67,000</td><td align="center" rowspan="1" colspan="1">221,000&#x000b1;68,200</td><td align="center" rowspan="1" colspan="1">0.81</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>MPV-ca=mean platelet volume (control angiography); MPV-d=mean platelet
volume (diagnosis); PDW-ca=platelet distribution width (control
angiography); PDW-d=platelet distribution width (diagnosis)</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Comparison of preoperative and postoperative MPV, PDW, and platelet count of
patients with saphenous vein graft disease (stenosis group).</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Preoperative</th><th align="center" rowspan="1" colspan="1">Postoperative</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">MPV</td><td align="center" rowspan="1" colspan="1">7.8&#x000b1;0.9</td><td align="center" rowspan="1" colspan="1">9.6&#x000b1;1.8</td><td align="center" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">PDW</td><td align="center" rowspan="1" colspan="1">16.6&#x000b1;0.9</td><td align="center" rowspan="1" colspan="1">16.5&#x000b1;1.5</td><td align="center" rowspan="1" colspan="1">0.59</td></tr><tr><td align="left" rowspan="1" colspan="1">Platelet count</td><td align="center" rowspan="1" colspan="1">221,000&#x000b1;68,200</td><td align="center" rowspan="1" colspan="1">272,000&#x000b1;93,300</td><td align="center" rowspan="1" colspan="1">0.003</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p>MPV=mean platelet volume; PDW=platelet distribution width</p></fn></table-wrap-foot></table-wrap><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>The receiver operating characteristic (ROC) curve of postoperative MPV,
PDW, and platelet count ratio for the prediction of saphenous vein graft
disease (stenosis group). Occlusion was determined by coronary
angiography artery within 3.2&#x000b1;2.4 years after CABG.</p><p>AUC=area under the curve; CABG=coronary artery bypass graft; MPV=mean
platelet volume; PDW=platelet distribution width</p></caption><graphic xlink:href="rbccv-33-04-0317-g01"/></fig>
</p><p>
<fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Comparison of mean platelet volume (MPV) in stenotic and nonstenotic
groups.</p></caption><graphic xlink:href="rbccv-33-04-0317-g02"/></fig>
</p><p>A comparison was made between patients who died at an early stage and surviving
patients regarding MPV-d, PDW-d, and platelet count-d values. MPV-d values in the
early death group were found to be higher than in surviving patients (9.4&#x000b1;1.9
fl and 8.0&#x000b1;1.0 fl, respectively; <italic>P</italic>&#x0003c;0.05). There was no
statistically significant difference with regards to PDW-d and platelet count-d
values (<italic>P</italic>&#x0003e;0.05) (<xref rid="t4" ref-type="table">Table
4</xref>). ROC curves for MPV-d, PDW-d, and platelet count-d in the early death
group are shown in <xref ref-type="fig" rid="f3">Figure 3</xref>. An MPV value
higher than 7.9 fl had 80% sensitivity and 68% specificity.</p><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Comparison of MPV, PDW, and platelet count of deceased and surviving
patients.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Early death<break/>(n=30)</th><th align="center" rowspan="1" colspan="1">Surviving patients (n=98)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">MPV-d</td><td align="center" rowspan="1" colspan="1">9.4&#x000b1;1.9</td><td align="center" rowspan="1" colspan="1">8.0&#x000b1;1.0</td><td align="center" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">PDW-d</td><td align="center" rowspan="1" colspan="1">16.9&#x000b1;1.1</td><td align="center" rowspan="1" colspan="1">15.8&#x000b1;2.1</td><td align="center" rowspan="1" colspan="1">0.08</td></tr><tr><td align="left" rowspan="1" colspan="1">Platelet count-d</td><td align="center" rowspan="1" colspan="1">248,000&#x000b1;97,600</td><td align="center" rowspan="1" colspan="1">260,000&#x000b1;97,600</td><td align="center" rowspan="1" colspan="1">0.2</td></tr></tbody></table><table-wrap-foot><fn id="TFN4"><p>MPV-d=mean platelet volume (diagnosis); PDW-d=platelet distribution width
(diagnosis)</p></fn></table-wrap-foot></table-wrap><p>
<fig id="f3" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>MPV and PDW values and platelet count of deceased patients at the time of
diagnosis.</p><p>AUC=area under the curve; MPV=mean platelet volume; PDW=platelet
distribution width; ROC=receiver operating characteristic</p></caption><graphic xlink:href="rbccv-33-04-0317-g03"/></fig>
</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>CABG surgery has been accepted as one of the most effective treatment modalities for
coronary artery disease. However, long-term outcomes are limited to
SVGD<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>.
Several risk factors, such as hypertension, diabetes mellitus, cigarette smoking,
hyperlipidemia, native vessel diameter, age of the graft, severity of bypassed
proximal vessel stenosis, plasma lipoprotein (a), homocysteine, and fibrinogen
levels, have been identified for SVGD. In addition, harvesting of venous grafts has
been found to be associated with endothelial injury during or after surgery, which
may also contribute to SVGD<sup>[<xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r7" ref-type="bibr">7</xref>]</sup>. Unlike with
arterial grafts, venous grafts are more sensitive to intimal hyperplasia,
atherosclerosis, progressive stenosis, and occlusion. All stages of the pathological
process are closely related to platelet and platelet functions. Although the role of
platelets in the vein graft disease has been evaluated, their relationship has not
yet been classified<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>.</p><p>Steele et al.<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>
demonstrated the relationship between occlusion of the saphenous vein graft and
platelet viability. Similarly, Latour et al.<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup> found platelet regeneration time reduced in
patients with saphenous bypass graft. Enzymatic and metabolic activity of the
platelets was reported to increase with an augmentation in the platelet volume.
Vasoactive mediators secreted by the platelets may contribute to inflammation and
the process of atherogenesis. Increased risk of acute coronary syndrome in patients
with high MPV may be explained by increased platelet activity, inflammation, and
platelet aggregation<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>. MPV has been found to be more closely related to
platelet function than to platelet count. In addition to the platelet count, several
factors were shown to affect platelet function, including platelet size, density,
age, and previous hemostatic interactions<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>.</p><p>The increase in MPV may be due to the depletion of small platelets during
ischemia<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>. Hemostatically reactive platelets, with more granular and
larger platelets with adhesion receptors resulting in decreased bleeding time,
showed an increased activity<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>. As a result, in addition to reflecting platelet count,
MPV also demonstrated platelet activity, and it was considered a determining factor
in atherosclerotic coronary disease<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>. Many studies have also shown that increased
platelet activation and aggregation are closely correlated with cardiovascular
complications<sup>[<xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r8" ref-type="bibr">8</xref>,<xref rid="r9" ref-type="bibr">9</xref>]</sup>. Tavil et
al.<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup> found
that MPV values were higher in the stenotic group when they compared patients with
SVGD and without SVGD, according to the results of coronary angiography after
coronary bypass surgery, and they identified MPV as a possible postoperative
indicator of graft success.</p><p>In the present study, we found MPV values significantly high during the development
of SVGD and in early (premature) death. This finding may be attributed to intimal
hyperplasia in patients with SVGD and to the result of atherosclerosis in increased
thrombosis, causing megakaryocyte and platelet activities increased in the bone
marrow of the ongoing thrombotic event. High platelet volume in patients with SVGD
and in those with premature death supports this notion. We could not demonstrate any
difference with regards to PDW and platelet count.</p><p>Platelet activation and venous graft thrombosis are considered early steps in the
stenosis and occlusion process after CABG surgery. Although many studies have shown
the efficacy of antiplatelet therapy during postoperative period, there is still no
consensus on the dose of this treatment and whether it should be used as a single
acetylsalicylic acid (ASA) drug or as combination therapy (ASA +
Clopidogrel)<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>. In our study, high MPV values in patients with
mortality and stenosis suggest that antiplatelet therapy should be widely used in
these patients during postoperative period.</p><p>In the present study, the difference in EF between the groups can be associated with
SVG occlusion as previously shown<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>. This suggests that poor left ventricular function
contributes to SVGD.</p><sec><title>Limitation</title><p>The main limitation of this study was its small sample size with a retrospective
design. However, the inclusion of patients with premature death after CABG
surgery and those with acute coronary syndrome and the presence of diagnostic
and postoperative data were the advantages of this study.</p></sec></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>The present study revealed a cut-off MPV value for the prediction of SVG patency
after CABG surgery. We believe that MPV could be used as a determinant of graft
patency and mortality after this surgery. Furthermore, MPV values can be considered
when deciding on the intensity of postoperative antiplatelet therapy.</p><table-wrap id="t6" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="95%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">UK</td><td align="left" rowspan="1" colspan="1">Substantial contributions to the conception or design
of the study; or the acquisition, analysis, or interpretation of
data for the study; final approval of the version to be
published</td></tr><tr><td align="left" rowspan="1" colspan="1">YK</td><td align="left" rowspan="1" colspan="1">Final approval of the version to be published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at Department of Cardiovascular Surgery, Ataturk
University, Faculty of Medicine, Erzurum, Turkey.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><fn-group><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldman</surname><given-names>S</given-names></name><name><surname>Zadina</surname><given-names>K</given-names></name><name><surname>Moritz</surname><given-names>T</given-names></name><name><surname>Ovitt</surname><given-names>T</given-names></name><name><surname>Sethi</surname><given-names>G</given-names></name><name><surname>Copeland</surname><given-names>JG</given-names></name><etal/><collab>VA Cooperative Study Group #207/297/364</collab></person-group><article-title>Long-term patency of saphenous vein and left internal mammary
artery grafts after coronary artery bypass surgery: results from a
Department of Veterans Affairs Cooperative Study</article-title><source>J Am Coll Cardiol</source><year>2004</year><volume>44</volume><issue>11</issue><fpage>2149</fpage><lpage>2156</lpage><pub-id pub-id-type="pmid">15582312</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motwani</surname><given-names>JG</given-names></name><name><surname>Topol</surname><given-names>EJ</given-names></name></person-group><article-title>Aortocoronary saphenous vein graft disease: pathogenesis,
predisposition, and prevention</article-title><source>Circulation</source><year>1998</year><volume>97</volume><issue>9</issue><fpage>916</fpage><lpage>931</lpage><pub-id pub-id-type="pmid">9521341</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tavil</surname><given-names>Y</given-names></name><name><surname>&#x0015e;en</surname><given-names>N</given-names></name><name><surname>Yazici</surname><given-names>HU</given-names></name><name><surname>Hizal</surname><given-names>F</given-names></name><name><surname>A&#x000e7;ikg&#x000f6;z</surname><given-names>SK</given-names></name><name><surname>Turfan</surname><given-names>M</given-names></name><etal/></person-group><article-title>Relationship between elevated platelet volume and saphenous vein
graft disease</article-title><source>Clin Invest Med</source><year>2010</year><volume>33</volume><issue>3</issue><fpage>E161</fpage><lpage>E167</lpage><pub-id pub-id-type="pmid">20519094</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ege</surname><given-names>MR</given-names></name><name><surname>Guray</surname><given-names>U</given-names></name><name><surname>Guray</surname><given-names>Y</given-names></name><name><surname>A&#x000e7;&#x00131;kg&#x000f6;z</surname><given-names>S</given-names></name><name><surname>Demirkan</surname><given-names>B</given-names></name></person-group><article-title>Platelet distribution width and saphenous vein disease in
patients after CABG. Association with graft occlusion</article-title><source>Herz</source><year>2013</year><volume>38</volume><issue>2</issue><fpage>197</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">22955688</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frey</surname><given-names>RR</given-names></name><name><surname>Bruschke</surname><given-names>AV</given-names></name><name><surname>Vermeulen</surname><given-names>FE</given-names></name></person-group><article-title>Serial angiographic evaluation 1 year and 9 years after
aorta-coronary bypass. A study of 55 patients chosen at
random</article-title><source>J Thorac Cardiovasc Surg</source><year>1984</year><volume>87</volume><issue>2</issue><fpage>167</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">6607386</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campeau</surname><given-names>L</given-names></name><name><surname>Enjalbert</surname><given-names>M</given-names></name><name><surname>Lesp&#x000e9;rance</surname><given-names>J</given-names></name><name><surname>Bourassa</surname><given-names>MG</given-names></name><name><surname>Kwiterovich Jr</surname><given-names>P</given-names></name><name><surname>Wacholder</surname><given-names>S</given-names></name><etal/></person-group><article-title>The relation of risk factors to the development of
atherosclerosis in saphenous-vein bypass grafts and the progression of
disease in the native circulation. A study 10 years after aortocoronary
bypass surgery</article-title><source>N Engl J Med</source><year>1984</year><volume>311</volume><issue>21</issue><fpage>1329</fpage><lpage>1332</lpage><pub-id pub-id-type="pmid">6333635</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoff</surname><given-names>HF</given-names></name><name><surname>Beck</surname><given-names>GJ</given-names></name><name><surname>Skibinski</surname><given-names>CI</given-names></name><name><surname>J&#x000fc;rgens</surname><given-names>G</given-names></name><name><surname>O'Neil</surname><given-names>J</given-names></name><name><surname>Kramer</surname><given-names>J</given-names></name><etal/></person-group><article-title>Serum Lp(a) level as a predictor of vein graft stenosis after
coronary artery bypass surgery in patients</article-title><source>Circulation</source><year>1988</year><volume>77</volume><issue>6</issue><fpage>1238</fpage><lpage>1244</lpage><pub-id pub-id-type="pmid">2967127</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steele</surname><given-names>P</given-names></name><name><surname>Battock</surname><given-names>D</given-names></name><name><surname>Pappas</surname><given-names>G</given-names></name><name><surname>Genton</surname><given-names>E</given-names></name></person-group><article-title>Correlation of platelet survival time with occlusion of saphenous
vein aorto-coronary bypass grafts</article-title><source>Circulation</source><year>1976</year><volume>53</volume><issue>4</issue><fpage>685</fpage><lpage>687</lpage><pub-id pub-id-type="pmid">1082802</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Latour</surname><given-names>JG</given-names></name><name><surname>Trudel</surname><given-names>JR</given-names></name><name><surname>Campeau</surname><given-names>L</given-names></name><name><surname>C&#x000f4;t&#x000e9;</surname><given-names>P</given-names></name><name><surname>Bourassa</surname><given-names>MG</given-names></name><name><surname>Corbara</surname><given-names>F</given-names></name><etal/></person-group><article-title>Platelet regeneration time and late occlusion of aortocoronary
saphenous vein bypass grafts</article-title><source>Can Med Assoc J</source><year>1980</year><volume>122</volume><issue>12</issue><fpage>1390</fpage><lpage>1393</lpage><pub-id pub-id-type="pmid">6973384</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x000d6;zl&#x000fc;</surname><given-names>MF</given-names></name><name><surname>&#x000d6;zt&#x000fc;rk</surname><given-names>S</given-names></name><name><surname>Ayhan</surname><given-names>SS</given-names></name><name><surname>Tosun</surname><given-names>M</given-names></name><name><surname>Al&#x000e7;elik</surname><given-names>A</given-names></name><name><surname>Erdem</surname><given-names>A</given-names></name><etal/></person-group><article-title>value of mean platelet volume in young patients with
non-ST-segment elevation acute coronary syndromes: a retrospective
observational study</article-title><source>Anadolu Kardiyol Derg</source><year>2013</year><volume>13</volume><issue>1</issue><fpage>57</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">23086804</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sewell</surname><given-names>R</given-names></name><name><surname>Ibbotson</surname><given-names>RM</given-names></name><name><surname>Philips</surname><given-names>R</given-names></name><name><surname>Carson</surname><given-names>P</given-names></name></person-group><article-title>High mean platelet volume after myocardial infarction: is it due
to consumption of small platelets?</article-title><source>Br Med J (Clin Res Ed)</source><year>1984</year><volume>289</volume><issue>6458</issue><fpage>1576</fpage><lpage>1578</lpage></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>JF</given-names></name><name><surname>Trowbridge</surname><given-names>EA</given-names></name><name><surname>Salmon</surname><given-names>G</given-names></name><name><surname>Plumb</surname><given-names>J</given-names></name></person-group><article-title>The biological significance of platelet volume: its relationship
to bleeding time, thromboxane B2 production and megakaryocyte nuclear DNA
concentration</article-title><source>Thromb Res</source><year>1983</year><volume>32</volume><issue>5</issue><fpage>443</fpage><lpage>460</lpage><pub-id pub-id-type="pmid">6658722</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erhart</surname><given-names>S</given-names></name><name><surname>Beer</surname><given-names>JH</given-names></name><name><surname>Reinhart</surname><given-names>WH</given-names></name></person-group><article-title>Influence of aspirin on platelet count and volume in
humans</article-title><source>Acta Haematol</source><year>1999</year><volume>101</volume><issue>3</issue><fpage>140</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">10352333</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bomb</surname><given-names>R</given-names></name><name><surname>Oliphant</surname><given-names>CS</given-names></name><name><surname>Khouzam</surname><given-names>RN</given-names></name></person-group><article-title>Dual antiplatelet therapy after coronary artery bypass grafting
in the setting of acute coronary syndrome</article-title><source>Am J Cardiol</source><year>2015</year><volume>116</volume><issue>1</issue><fpage>148</fpage><lpage>154</lpage><pub-id pub-id-type="pmid">25933730</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brodie</surname><given-names>BR</given-names></name><name><surname>VerSteeg</surname><given-names>DS</given-names></name><name><surname>Brodie</surname><given-names>MM</given-names></name><name><surname>Hansen</surname><given-names>C</given-names></name><name><surname>Richter</surname><given-names>SJ</given-names></name><name><surname>Stuckey</surname><given-names>TD</given-names></name><etal/></person-group><article-title>Poor long-term patient and graft survival after primary
percutaneous coronary intervention for acute myocardial infarction due to
saphenous vein graft occlusion</article-title><source>Catheter Cardiovasc Interv</source><year>2005</year><volume>65</volume><issue>4</issue><fpage>504</fpage><lpage>509</lpage><pub-id pub-id-type="pmid">15988742</pub-id></element-citation></ref></ref-list></back></article>